Summary & Overview
HCPCS G9131: Invasive Female Breast Cancer Disease Status, Staging
HCPCS Level II code G9131 denotes an oncology-focused disease status classification for invasive female breast cancer (adenocarcinoma predominant) when the extent of disease is unknown, staging is in progress, or staging is not listed. The code is designated for use in a Medicare-approved demonstration project and reflects encounters tied to diagnostic classification and staging processes rather than a specific therapeutic procedure. Nationally, accurate use of this HCPCS code matters for consistent documentation in oncology care pathways and for tracking staging-related activities in demonstration projects that inform broader policy.
Key payers considered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the clinical context of the code, the likely service setting and activity it represents, and the types of benchmarks and policy implications typically associated with demonstration-project codes. The publication outlines expected uses of the code in staging workflows, discusses implications for billing and reporting in oncology settings, and highlights where input data is not available. Data not available in the input includes detailed payer-specific coverage rules, associated taxonomies, ICD-10 codes, related billing codes, and specific service line categorizations.
Billing Code Overview
HCPCS Level II code G9131 describes a classification used in oncology for disease status assessment of invasive female breast cancer (excluding ductal carcinoma in situ), where adenocarcinoma is the predominant cell type and the extent of disease is unknown, staging is in progress, or staging is not listed. The code is specified for use in a Medicare-approved demonstration project.
-
Service type: Oncology disease status assessment and staging activities related to invasive female breast cancer.
-
Typical site of service: Hospital outpatient setting, oncology clinic, or other cancer care facility where staging workup and disease-status evaluations are performed.
Data not available in the input for payers beyond the demonstration project, associated taxonomies, ICD-10 diagnoses, related codes, and service line.
Clinical & Coding Specifications
Clinical Context
A typical patient is a woman referred to an oncology clinic after a suspicious breast mass or abnormal imaging. She has invasive female breast cancer (adenocarcinoma predominant) where the extent of disease is not yet determined or staging is in progress. Initial workflow includes history and physical, diagnostic mammography and breast ultrasound, core needle biopsy confirming invasive adenocarcinoma, and multi‑disciplinary staging orders (breast MRI, chest CT, bone scan or PET-CT as indicated). The oncology team documents disease status for a Medicare-approved demonstration project using billing code G9131. Clinical encounters include discussion of biopsy results, staging test coordination, documentation of clinical stage (tumor, node, metastasis) as pending or unknown, and recording of planned management (surgery, systemic therapy, radiation) pending completion of staging. Typical sites of service are outpatient oncology clinic, breast center, or hospital outpatient radiology for imaging and staging procedures. Common patient scenario modifiers include complex visit time or concurrent administrative needs when staging is delayed or additional information is required prior to definitive treatment decisions.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
22 | Increased procedural services | Use when services require substantially greater effort or complexity than typical (e.g., unusually complex staging coordination or extensive documentation for demonstration project reporting). |